|
Metastatic breast cancer guidelines workshop: Managing metastatic breast cancer : the European School of Oncology - Metastatic Breast Cancer Task Force session
|
 |
S. Kyriakides (Cyprus) |
What patients need their doctors to focus on: the patient's perspective |
|
L. Fallowfield (United Kingdom) |
What patients with MBC need |
|
D.A. Cameron (United Kingdom) |
What patients need their doctors to focus on: the doctor's perspective |
|
P. Francis (Australia) |
How many lines of therapy should be given? |
|
J. Gligorov (France) |
Role of maintenance therapy |
|
Teaching Lecture: Breast cancer in the elderly
|
|
M. Aapro (Switzerland) |
Breast cancer in the elderly |
|
Teaching Lecture: Statistical issues in the validation of biomarkers and surrogate endpoints
|
|
M. Buyse (Belgium) |
Statistical issues in the validation of biomarkers and surrogate endpoints |
|
Debate: This house believes that follow up by a medical cancer specialist is necessary
|
|
M. Untch (Germany) |
|
|
E. Grunfeld (Canada) |
The argument against |
|
D. Montgomery (United Kingdom) |
The case against |
|
Debate: This house believes that MRI for breast cancer is standard of care
|
|
U. Nitz (Germany) |
Pro MRI |
|
M. Dixon (United Kingdom) |
|
|
Keynote symposium: Best and practice changing abstracts
|
|
P. Romestaing (France) |
Elective irradiation of Internal Mammary Chain (IMC) after mastectomy has no impact on 10y overall survival in breast cancer - results of a randomized phase III study in France |
|
P. Poortmans (The Netherlands) |
Irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer: state of the day of EORTC phase III trial 22922/10925 with 4004 patients |
|
T.A. Buchholz (USA) |
Local management of Pts with a BRCA mutation.
Should the IM lymph nodes be a target for radiation treatment?
|
|
M. Andersson (Denmark) |
Similar outcome in a randomized phase III trial comparing docetaxel versus vinorelbine both combined with trastuzumab as first line treatment for metastatic or locally advanced human epidermal growth factor receptor 2 (HER2) positive breast cancer |